The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
Open accessAbstract
Background: Ibrutinib is a Bruton tyrosine kinase inhibitor that is used for the treatment of lymphoid cancers, including chronic lymphocytic leukemia, Waldenström macroglobulinemia, and mantle cell lymphoma. Several case series have described opportunistic infections among ibrutinib recipients, but the full extent of these infections is unknown. We sought to determine the spectrum of serious infections associated with ibrutinib treatment. Methods: We reviewed the electronic medical records of patients with lymphoid cancer at Memorial Sloan Kettering Cancer Center who received ibrutinib during a 5-year period from 1 January 2012 to 31 December 2016. Serious infections were identified by review of the relevant microbiology, clinical laboratory, and radiology data. Risk factors for infection were determined by means of univariate and multivariate analyses. Results: We analyzed findings in 378 patients with lymphoid cancer who received ibrutinib. The most common underlying cancers were chronic lymphocytic leukemia and mantle cell lymphoma. 84% of patients received ibrutinib as monotherapy. Serious infection developed in 43 patients (11.4%), primarily during the first year of ibrutinib treatment. Invasive bacterial infections developed in 23 (53.5%) of these patients, and invasive fungal infections (IFIs) in 16 (37.2%) .The majority of patients with IFIs during ibrutinib therapy (62.5%) lacked classic clinical risk factors for fungal infection (ie, neutropenia, lymphopenia, and receipt of corticosteroids). Infection resulted in death in 6 of the 43 patients (14%). Conclusions: Patients with lymphoid cancer receiving ibrutinib treatment are at risk for serious infections, including IFIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, treatment of patients with lymphoproliferative malignancies with inhibitors of BTK has resulted in a surge in cases of invasive aspergillosis (79, 264).”
From Aspergillus fumigatus and Aspergillosis in 2019 (2019) · cites this paper as [264]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Vetrie, D. L. P., Vořechovský, I., Sideras, P., Holland, J., Davies, A. F., Flinter, F. A., Hammarström, L. L. G., Kinnon, C., Levinsky, R. J., Bobrow, M., et al. (1993) · Nature · doi:10.1038/361226a0 · Cited by 1,465
Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia
Tsukada, S., Saffran, D. C., Rawlings, D. J., Parolini, O., Allen, R. C., Klisak, I. J., Sparkes, R. S., Kubagawa, H., Mohandas, T. K., Quan, S. G., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90667-f · Cited by 1,326
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 3×
“Ibrutinib was approved by the US Food and Drug Administration for the treatment of patients with CLL, previously treated mantle cell lymphoma (MCL) or marginal zone lymphoma, WM, or refractory chronic graft-versus-host disease, and by the European Medicines Agency for the treatment of patients with CLL, WM, or previou…”
MethodIbrutinib in Previously Treated Waldenström’s Macroglobulinemia
Treon, S. P., Tripsas, C. K., Meid, K., Warren, D. L., Varma, G., Green, R., Argyropoulos, K. V., Yang, G., Cao, Y., Xu, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501548 · Cited by 951
Self-citationByrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 674
Colocalization of X-Linked Agammaglobulinemia and X-Linked Immunodeficiency Genes
Thomas, J. D., Sideras, P., Smith, C. I. E., Vořechovský, I., Chapman, V. M., & Paul, W. E. (1993) · Science · doi:10.1126/science.8332900 · Cited by 613
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
Miklos, D. B., Cutler, C. S., Arora, M., Waller, E. K., Jagasia, M., Pusic, I., Flowers, M. E. D., Logan, A. C., Nakamura, R., Blazar, B. R., et al. (2017) · Blood · doi:10.1182/blood-2017-07-793786 · Cited by 520
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Lionakis, M. S., Dunleavy, K. M., Roschewski, M. J., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C. J., Higham, C. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.012 · Cited by 518
Mohamed, A. J., Yu, L., Bäckesjö, C., Vargas, L., Faryal, R., Aints, A., Christensson, B., Berglöf, A., Vihinen, M., Nore, B. F., et al. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00741.x · Cited by 516
O'Brien, S. M., Furman, R. R., Coutre, S. E., Sharman, J. P., Burger, J. A., Blum, K. A., Grant, B., Richards, D., Coleman, M., Wierda, W. G., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70513-8 · Cited by 469
Burger, J. A., Keating, M. J., Wierda, W. G., Hartmann, E., Hoellenriegel, J., Rosin, N. Y., de Weerdt, I., Jeyakumar, G., Ferrajoli, A., Cárdenas-Turanzas, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70335-3 · Cited by 337
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
Ghez, D., Calleja, A., Protin, C. A., Baron, M., Ledoux, M., Damaj, G. L., Dupont, M., Dreyfus, B., Ferrant, E., Herbaux, C., et al. (2018) · Blood · doi:10.1182/blood-2017-11-818286 · Cited by 320
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Noy, A., de Vos, S., Thiéblemont, C., Martin, P., Flowers, C. R., Morschhauser, F., Collins, G. P., Ma, S., Coleman, M., Peles, S., et al. (2017) · Blood · doi:10.1182/blood-2016-10-747345 · Cited by 303
Chamilos, G., Lionakis, M. S., & Kontoyiannis, D. P. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix687 · Cited by 267
X-Linked Agammaglobulinemia A Clinical and Molecular Analysis
Ochs, H. D., & Smith, C. I. E. (1996) · Medicine · doi:10.1097/00005792-199611000-00001 · Cited by 266
Younes, A., Thiéblemont, C., Morschhauser, F., Flinn, I. W., Friedberg, J. W., Amorim, S., Hivert, B., Westin, J. R., VERMEULEN, J. T., Bandyopadhyay, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70311-0 · Cited by 257
Ahn, I. E., Jerussi, T., Farooqui, M. Z. H., Tian, X., Wiestner, A. U., & Gea‐Banacloche, J. (2016) · Blood · doi:10.1182/blood-2016-06-722991 · Cited by 165
Jongstra‐Bilen, J., Cano, A. P., Hasija, M., Xiao, H., Smith, C. I. E., & Cybulsky, M. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.288 · Cited by 132
Bruton’s tyrosine kinase (BTK) as a promising target in solid tumors
Molina‐Cerrillo, J., Alonso‐Gordoa, T., Gajate, P., & Grande, E. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.001 · Cited by 130
Strijbis, K., Tafesse, F., Fairn, G. D., Witte, M. D., Dougan, S. K., Watson, N., Spooner, E., Esteban, A., Vyas, V. K., Fink, G. R., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003446 · Cited by 88
Montagna, M. T., Giglio, O. D., Napoli, C., Lovero, G., Caggiano, G., Delia, M., Pastore, D., Santoro, N., & Specchia, G. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13010774 · Cited by 67
Baron, M., Zini, J. M., Challan-Belval, T., Vignon, M., Denis, B., Alanio, A., & Malphettes, M. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1320710 · Cited by 62
Targeting Bruton's tyrosine kinase with ibrutinib in B‐cell malignancies
Wang, Y., Zhang, L., Champlin, R., & Ml, W. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.85 · Cited by 60
Messina, J. A., Maziarz, E. K., Spec, A., Kontoyiannis, D. P., & Perfect, J. R. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw261 · Cited by 57
Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
Arthurs, B. J., Wunderle, K., Hsu, M., & Kim, S. (2017) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2017.03.011 · Cited by 57
Ibrutinib for Chronic Lymphocytic Leukemia
Burger, J. A., Styles, L. A., & Kipps, T. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1600328 · Cited by 53
Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib
Okamoto, K., Proia, L. A., & Demarais, P. (2016) · Case Reports in Infectious Diseases · doi:10.1155/2016/4642831 · Cited by 45
Current Status of Bruton’s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies
Aw, A., & Brown, J. R. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0468-4 · Cited by 43
Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia
Chan, T. S. Y., Au-Yeung, R. K. H., Ho, P., Wong, S. C. Y., & Kwong, Y. (2017) · Annals of Hematology · doi:10.1007/s00277-017-2944-7 · Cited by 31
Ibrutinib in Chronic Lymphocytic Leukemia
Reddy, N. M., & Sethi, T. K. (2015) · International Journal of Hematologic Oncology · doi:10.2217/ijh.15.15 · Cited by 26
Ibrutinib‐associated Pneumocystis jirovecii pneumonia
Lee, R., Nayernama, A., Jones, S. C., Wroblewski, T., & Waldron, P. E. (2017) · American Journal of Hematology · doi:10.1002/ajh.24890 · Cited by 25
Visentin, A., Gurrieri, C., Imbergamo, S., Lessi, F., Maggio, S. A. D., Frezzato, F., Adami, F., Zambello, R., Piazza, F., Semenzato, G., et al. (2016) · Hematological Oncology · doi:10.1002/hon.2343 · Cited by 22
X-Linked Agammaglobulinemia -- GeneReviews®
Ra, P., Adam, M. P., Hh, A., Se, W., Amemiya, A., Ljh, B., Bird, T. D., Ct, F., Mefford, H. C., Rjh, S., et al. (2016) · Cited by 2
Research works printed but not linked: 1
- Smith, 1993–2018, X-linked agammaglobulinemia
Cited by
Sorted by citations
Aspergillus fumigatus and Aspergillosis in 2019
Latgé, J.-P., & Chamilos, G. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00140-18 · Cited by 1,400
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
Estupiñan, H. Y., Berglöf, A., Zain, R., & Smith, C. I. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.630942 · Cited by 274
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E. K., Gedye, C. A., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 193
(ECIL), O. B. O. T. E. C. O. I. I. L., Maschmeyer, G., Greef, J. D., Mellinghoff, S. C., Nosari, A., Thiébaut, A., Bergeron, A., Franquet, T., Blijlevens, N. M. A., & Maertens, J. A. (2019) · Leukemia · doi:10.1038/s41375-019-0388-x · Cited by 188
Managing toxicities of Bruton tyrosine kinase inhibitors
Lipsky, A. H., & Lamanna, N. (2020) · Hematology · doi:10.1182/hematology.2020000118 · Cited by 174
Metadata
- Authors
- Varughese, T., Taur, Y., Cohen, N., Palomba, M. L., Seo, S. K., Hohl, T. M., & Redelman-Sidi, G.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Infectious Diseases Service, Memorial Sloan Kettering Cancer Center
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-27
- Volume
- 67
- Issue
- 5
- Pages
- 687-692
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC6093991
- OpenAlex
- W2789508123
- Cited by
- 271
- References
- 36
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 25 · 2023: 25 · 2022: 26 · 2021: 50 · 2020: 56 · 2019: 36 · 2018: 15
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30 CA008748)
- National Institutes of Health (K08 CA184038)
- Topics
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- ibrutinib, serious infections, lymphoid malignancies, chronic lymphocytic leukemia, mantle cell lymphoma, Waldenström macroglobulinemia, BTK inhibitors, invasive fungal infections, invasive bacterial infection, infection risk factors, opportunistic infections
- MeSH terms
- Invasive Fungal Infections, Adenine, Adult, Aged, Aged, 80 and over, Bacterial Infections, Female, Humans, Lymphopenia, Male, Middle Aged, New York, Opportunistic Infections, Piperidines, Pyrazoles, Pyrimidines, Risk Factors, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell, Young Adult, Electronic Health Records
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
